Companies › Satellos Bioscience
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SAT-3247 AAK1 inhibitor that promotes functional rescue of asymmetric satellite cell division | AAK1 | Phase 2 | Duchenne Muscular Dystrophy | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07287189 | SAT-3247 | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Mar 2027 |
Cash and short-term investments of $28m on 2025-12-31; operating cash outflow about $24m a year; runway about 14 months at that burn, to Mar 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Coya Therapeutics PepGen Cognition Therapeutics DiaMedica Therapeutics IGC Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.